2seventy bio (TSVT) News Today $3.08 -0.13 (-4.05%) (As of 10:03 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analysts Issue Forecasts for 2seventy bio FY2024 EarningsDecember 8, 2024 | americanbankingnews.com2seventy bio: Buy Rating Amidst Challenges and Growth Potential in BCMA CAR-T TherapyDecember 6, 2024 | markets.businessinsider.comLeerink Partnrs Reduces Earnings Estimates for 2seventy bio2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for 2seventy bio in a report released on Wednesday, December 4th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($December 6, 2024 | marketbeat.comWestern Standard LLC Takes Position in 2seventy bio, Inc. (NASDAQ:TSVT)Western Standard LLC acquired a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 285,931 shares of the company's stock, valued at apprDecember 6, 2024 | marketbeat.com2seventy bio (TSVT) Gets a Hold from Morgan StanleyDecember 6, 2024 | markets.businessinsider.com2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund reduced its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 59.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 590,000 shares of the company's stock aDecember 1, 2024 | marketbeat.comBBR Partners LLC Has $850,000 Position in 2seventy bio, Inc. (NASDAQ:TSVT)BBR Partners LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 620.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 180,000 shares of the company's stock after purchasing an additional 155,000November 28, 2024 | marketbeat.comMarcela V. Maus Sells 3,900 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockNovember 21, 2024 | insidertrades.comUS$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest ResultsNovember 15, 2024 | finance.yahoo.com2seventy bio Reports Strong Growth in Abecma SalesNovember 15, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on 2seventy bio (TSVT)November 15, 2024 | markets.businessinsider.com2seventy Bio's Losses Narrow, Sales DipNovember 13, 2024 | fool.com2seventy bio Inc (TSVT) Q3 2024 Earnings Call Highlights: Strong Abecma Growth and Strategic ...November 13, 2024 | finance.yahoo.com2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.com2seventy bio Earnings PreviewNovember 12, 2024 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTNovember 10, 2024 | prnewswire.com2seventy bio (TSVT) to Release Quarterly Earnings on Tuesday2seventy bio (NASDAQ:TSVT) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 5, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy bio (TSVT)November 5, 2024 | markets.businessinsider.com2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor ConferenceNovember 4, 2024 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTNovember 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 25, 2024 | prnewswire.comTD Cowen Sticks to Its Hold Rating for 2seventy bio (TSVT)October 22, 2024 | markets.businessinsider.com2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigneOctober 21, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 9, 2024 | prnewswire.comTSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmOctober 9, 2024 | globenewswire.comTSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmOctober 7, 2024 | prnewswire.comHealthcare of Ontario Pension Plan Trust Fund Sells 268,100 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)Healthcare of Ontario Pension Plan Trust Fund cut its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 15.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,468,500 shares of the company's stockOctober 6, 2024 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Shares Bought by Marshall Wace LLPMarshall Wace LLP boosted its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 50.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 667,023 shares of the company's stock after purchasing an aOctober 4, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 3, 2024 | prnewswire.comTSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmSeptember 29, 2024 | prnewswire.com2seventy bio, Inc. (NASDAQ:TSVT) Sees Significant Decrease in Short Interest2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 5,130,000 shares, a decline of 13.8% from the August 31st total of 5,950,000 shares. Approximately 10.6% of the shares of the company are sold short. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is presently 12.8 days.September 28, 2024 | marketbeat.comBuy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive OutlookSeptember 28, 2024 | markets.businessinsider.comTSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmSeptember 27, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTSeptember 27, 2024 | prnewswire.comPetri Dish: 2seventy, BMS halt Phase 3 trial; Flagship spinout names CSOSeptember 26, 2024 | bizjournals.com2seventy bio, Inc. (NASDAQ:TSVT) Given Average Rating of "Moderate Buy" by Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, four havSeptember 26, 2024 | marketbeat.com2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick FactsSeptember 25, 2024 | markets.businessinsider.comBristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To ProfitabilitySeptember 25, 2024 | finance.yahoo.com2seventy Bio stops enrolling patients in blood cancer therapy studySeptember 25, 2024 | reuters.com2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed PatientsSeptember 25, 2024 | marketwatch.com2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue PerformanceSeptember 25, 2024 | finance.yahoo.com2seventy bio, Inc. (NASDAQ:TSVT) Shares Purchased by Venator Management LLCVenator Management LLC boosted its position in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 49.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 485,000 shares of the company's stock after acquiSeptember 19, 2024 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy bio (TSVT) and Repare Therapeutics (RPTX)August 30, 2024 | markets.businessinsider.com2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare ConferenceAugust 29, 2024 | finance.yahoo.comInsider Selling: 2seventy bio, Inc. (NASDAQ:TSVT) Insider Sells 7,816 Shares of StockAugust 19, 2024 | insidertrades.com2seventy bio, Inc. (NASDAQ:TSVT) Insider Jessica Snow Sells 7,816 Shares2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) insider Jessica Snow sold 7,816 shares of the firm's stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $4.32, for a total transaction of $33,765.12. Following the completion of the transaction, the insider now owns 156,330 shares in the company, valued at approximately $675,345.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.August 16, 2024 | marketbeat.comEarnings call: 2Seventy Bio sees progress with ABECMA in Q2 2024August 13, 2024 | uk.investing.com2seventy bio, Inc. (NASDAQ:TSVT) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | insidermonkey.com2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.com Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Is the Trump/Musk duo good for shares of TSLA? (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. TSVT Media Mentions By Week TSVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSVT News Sentiment▼-1.000.65▲Average Medical News Sentiment TSVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSVT Articles This Week▼12▲TSVT Articles Average Week Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tectonic Therapeutic News Today Prothena News Today CARGO Therapeutics News Today Stoke Therapeutics News Today Altimmune News Today Exscientia News Today Terns Pharmaceuticals News Today ORIC Pharmaceuticals News Today Phathom Pharmaceuticals News Today Tourmaline Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSVT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
